Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Viread (tenofovir) is highly effective at suppressing hepatitis B, even after an eight-year period.
Taking opioid maintenance therapy with methadone or buprenorphine is linked to a 61 percent reduced risk of hepatitis C virus (HCV) among youn...
Eight weeks of Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C, but yielded unsatisf...
Gilead Sciences’ newly approved Harvoni (ledipasvir/sofosbuvir) cured nearly all people with genotype 4 of hepatitis C in a small trial.
Hepatitis C treatments based on Gilead Sciences’ Sovaldi (sofosbuvir) are faring just as well in the real world as in clinical trials.
AbbVie’s ’3D’ regimen plus ribavirin cured all people with genotype 4 of hepatitis C in a recent trial, plus 91 percent of those with genotype...
Adding interferon to Viread (tenofovir) treatment for hepatitis B virus raised the likelihood of hep B surface antigen (HBsAg) loss in an ongo...
Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...
Sovaldi (sofosbuvir) and Olysio (simeprevir), with or without ribavirin, cures over 90 percent of people with hepatitis C who have had a liver...
Twelve weeks of Harvoni plus ribavirin cured nearly all highly treatment-experienced cirrhotic people with genotype 1 of hepatitis C virus.
HIV-positive people who have liver transplants because of liver cancer have high survival rates.
Twelve weeks of Gilead Sciences’ Harvoni cured high rates of genotypes 3 and 6 of hepatitis C virus, with and without ribavirin.
Americans receiving care through the VA are infrequently tested for hepatitis B, and only a fraction of those who test positive are treated or...
Twelve or 18 weeks of Merck?s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1...
Four weeks of Merck’s grazoprevir/elbasvir plus Gilead’s Sovaldi posted poor interim results in treating people with geno 1 of hepatitis C
Eight weeks of ACH-3102 and Sovaldi (sofosbuvir) cured 100 percent of treatment-naive people with genotype 1 of hepatitis C in a recent study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.